Pioglitazone attenuates acute cocaine toxicity in rat isolated heart: Potential protection by metabolic modulation

Anesthesiology

Volumn 114, Issue 6, 2011, Pages 1389-1395

  Weinberg, Guy L ^a,d   Ripper, Richard ^a   Bern, Sarah ^a   Lin, Bocheng ^a   Edelman, Lucas ^b   Digregorio, Guido ^c   Piano, Mariann ^a   Feinstein, Douglas L ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^d UNIVERSITY OF ILLINOIS HOSPITAL AND HEALTH SCIENCES SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARNITINE; COCAINE; LACTIC ACID; OCTANOYLCARNITINE; PIOGLITAZONE; PYRUVIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; CORONARY VASCULAR RESISTANCE; DIASTOLIC DYSFUNCTION; DRUG INTOXICATION; GLUCOSE METABOLISM; HEART MUSCLE CELL; ISOLATED HEART; MALE; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; MUSCLE CONTRACTILITY; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RAT;

EID: 79958078896     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e318218a7f6     Document Type: Conference Paper

References (34)

1. Lange RA, Cigarroa RG, Yancy CW Jr, Willard JE, Popma JJ, Sills MN, McBride W, Kim AS, Hillis LD: Cocaine-induced coronary-artery vasoconstriction. N Engl J Med 1989; 321: 1557-62.
2. Billman GE: Cocaine: A review of its toxic actions on cardiac function. Crit Rev Toxicol 1995; 25:113-32.
3. Morcos NC, Fairhurst A, Henry WL: Direct myocardial effects of cocaine. Cardiovasc Res 1993; 27:269-73. (Pubitemid 23070339)
4. Weinberg GL, Palmer JW, VadeBoncouer TR, Zuechner MB, Edelman G, Hoppel CL: Bupivacaine inhibits acylcarnitine exchange in cardiac mitochondria. ANESTHESIOLOGY 2000; 92: 523-8. (Pubitemid 30078352)
5. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270: 12953-6.
6. Rasouli N, Raue U, Miles LM, Lu T, Di Gregorio GB, Elbein SC, Kern PA: Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. Am J Physiol Endocrinol Metab 2005; 288: E930-4.
7. Dello Russo C, Gavrilyuk V, Weinberg G, Almeida A, Bolanos JP, Palmer J, Pelligrino D, Galea E, Feinstein DL: Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes. J Biol Chem 2003; 278:5828-36.
8. Brunmair B, Staniek K, Gras F, Scharf N, Althaym A, Clara R, Roden M, Gnaiger E, Nohl H, Waldhäusl W, Fürnsinn C: Thiazolidinediones, like metformin, inhibit respiratory complex I: A common mechanism contributing to their antidiabetic actions? Diabetes 2004; 53:1052-9. (Pubitemid 38436618)
9. Feinstein DL, Galea E, Gavrilyuk V, Brosnan CF, Whitacre CC, Dumitrescu-Ozimek L, Landreth GE, Pershadsingh HA, Weinberg G, Heneka MT: Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann Neurol 2002; 51:694-702. (Pubitemid 34568847)
10. Palmer JW, Tandler B, Hoppel CL: Biochemical properties of subsarcolemmal and interfibrillar mitochondria isolated from rat cardiac muscle. J Biol Chem 1977; 252:8731-9. (Pubitemid 8243644)
11. Liu D, Hariman RJ, Bauman JL: Cocaine concentration-effect relationship in the presence and absence of lidocaine: Evidence of competitive binding between cocaine and lidocaine. J Pharmacol Exp Ther 1996; 276:568-77.
12. Crumb WJ Jr, Clarkson CW: Characterization of cocaineinduced block of cardiac sodium channels. Biophys J 1990; 57:589-99. (Pubitemid 20090194)
13. Mittleman RE, Wetli CV: Death caused by recreational cocaine use. An update. JAMA 1984; 252:1889-93.
14. Rump AF, Theisohn M, Klaus W: The pathophysiology of cocaine cardiotoxicity. Forensic Sci Int 1995; 71:103-15.
15. Pitts WR, Lange RA, Cigarroa JE, Hillis LD: Cocaine-induced myocardial ischemia and infarction: Pathophysiology, recognition, and management. Prog Cardiovasc Dis 1997; 40: 65-76. (Pubitemid 27319122)
16. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J, PROactive investigators: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 2005; 366:1279-89.
17. Buchanan TA, Meehan WP, Jeng YY, Yang D, Chan TM, Nadler JL, Scott S, Rude RK, Hsueh WA: Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. J Clin Invest 1995; 96:354-60.
18. Powell JR, Feigl EO: Carotid sinus reflex coronary vasoconstriction during controlled myocardial oxygen metabolism in the dog. Circ Res 1979; 44:44-51. (Pubitemid 9089576)
19. Yuan C, Acosta D Jr: Effect of cocaine on mitochondrial electron transport chain evaluated in primary cultures of neonatal rat myocardial cells and in isolated mitochondrial preparations. Drug Chem Toxicol 2000;23:339-48. (Pubitemid 30317042)
20. Devi BG, Chan AW: Impairment of mitochondrial respiration and electron transport chain enzymes during cocaine-induced hepatic injury. Life Sci 1997; 60:849-55. (Pubitemid 27153450)
21. Vergeade A, Mulder P, Vendeville-Dehaudt C, Estour F, Fortin D, Ventura-Clapier R, Thuillez C, Monteil C: Mitochondrial impairment contributes to cocaine-induced cardiac dysfunction: Prevention by the targeted antioxidant MitoQ. Free Radic Biol Med 2010; 49:748-56.
22. Zhou L, Cabrera ME, Okere IC, Sharma N, Stanley WC: Regulation of myocardial substrate metabolism during increased energy expenditure: Insights from computational studies. Am J Physiol Heart Circ Physiol 2006; 291: H1036-46. (Pubitemid 44343647)
23. Svedjeholm R, Håkanson E, Szabó Z: Metabolic intervention for the ischemic and post-ischemic heart. Wien Klin Wochenschr 1999; 111:501-11. (Pubitemid 29344122)
24. Diaz R: Metabolic modulation of acute myocardial infarction. Crit Care Clin 2001; 17:469-76. (Pubitemid 32612725)
25. Díaz R, Paolasso EA, Piegas LS, Tajer CD, Moreno MG, Corvala ́n R, Isea JE, Romero G: Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiológicos Latinoamérica) Collaborative Group. Circulation 1998; 98: 2227-34.
26. Stanley WC, Lopaschuk GD, Hall JL, McCormack JG: Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions. Cardiovasc Res 1997; 33:243-57. (Pubitemid 27072627)
27. McCormack JG, Stanley WC, Wolff AA: Ranolazine: A novel metabolic modulator for the treatment of angina. Gen Pharmacol 1998; 30:639-45. (Pubitemid 28167764)
28. Weinberg G, VadeBoncouer T: Improved energetics may explain the favorable effect of insulin infusion on bupivacaine cardiotoxicity. Anesth Analg 2001; 92:1075-6. (Pubitemid 32239169)
29. Shiomi T, Tsutsui H, Hayashidani S, Suematsu N, Ikeuchi M, Wen J, Ishibashi M, Kubota T, Egashira K, Takeshita A: Pioglitazone, a peroxisome proliferator-activated receptorgamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002; 106:3126-32.
30. Khandoudi N, Delerive P, Berrebi-Bertrand I, Buckingham RE, Staels B, Bril A: Rosiglitazone, a peroxisome proliferatoractivated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. Diabetes 2002; 51: 1507-14.
31. Spagnolo A, Glick RP, Lin H, Cohen EP, Feinstein DL, Lichtor T: Prolonged survival of mice with established intracerebral glioma receiving combined treatment with peroxisome proliferator-activated receptor-gamma thiazolidinedione agonists and interleukin-2-secreting syngeneic/allogeneic fibroblasts. J Neurosurg 2007; 106:299-305. (Pubitemid 46203159)
32. Golfman LS, Wilson CR, Sharma S, Burgmaier M, Young ME, Guthrie PH, Van Arsdall M, Adrogue JV, Brown KK, Taegtmeyer H: Activation of PPARgamma enhances myocardial glucose oxidation and improves contractile function in isolated working hearts of ZDF rats. Am J Physiol Endocrinol Metab 2005; 289:E328-36. (Pubitemid 41076636)
33. Honda T, Kaikita K, Tsujita K, Hayasaki T, Matsukawa M, Fuchigami S, Sugiyama S, Sakashita N, Ogawa H, Takeya M: Pioglitazone, a peroxisome proliferator-activated receptorgamma agonist, attenuates myocardial ischemia-reperfusion injury in mice with metabolic disorders. J Mol Cell Cardiol 2008; 44:915-26.
34. Feinstein DL, Spagnolo A, Akar C, Weinberg G, Murphy P, Gavrilyuk V, Dello Russo C: Receptor-independent actions of PPAR thiazolidinedione agonists: Is mitochondrial function the key? Biochem Pharmacol 2005; 70:177-88 (Pubitemid 40814400)